HDAC3
Histone deacetylase 3
As of the edition of 20 October 2026, HDAC3 (histone deacetylase 3, UniProt O15379) has 4 drugs tested at it and 6 companies on the list, 2 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O15379
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 1
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue; Lungs and airways; Urinary and reproductive; Digestive system; Nervous system
- Registered trials of its drugs
- 476
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Stopped | 2 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Vorinostat | Marketed | Phase 3 | Ends 2027 |
| Tucidinostat | Marketed | Phase 4 | none listed |
| Nanatinostat | Stopped | Phase 2 | none listed |
| MTX110 | Stopped | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 1 |
| Engaged | 2 |
| Undetermined | 1 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Merck & Co. | Route B |
| Viracta Therapeutics | Route A |
| Biodexa Pharmaceuticals | Route A |
The other 3 companies at HDAC3
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at HDAC3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.